CN110917059A - Efficacy agent of toothpaste with anti-inflammation and hemostasis effects, toothpaste containing efficacy agent and preparation method of toothpaste - Google Patents
Efficacy agent of toothpaste with anti-inflammation and hemostasis effects, toothpaste containing efficacy agent and preparation method of toothpaste Download PDFInfo
- Publication number
- CN110917059A CN110917059A CN202010002447.8A CN202010002447A CN110917059A CN 110917059 A CN110917059 A CN 110917059A CN 202010002447 A CN202010002447 A CN 202010002447A CN 110917059 A CN110917059 A CN 110917059A
- Authority
- CN
- China
- Prior art keywords
- toothpaste
- parts
- extract
- phase
- efficacy agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000606 toothpaste Substances 0.000 title claims abstract description 72
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 70
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 62
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000023597 hemostasis Effects 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 60
- 230000000740 bleeding effect Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 20
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 17
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 17
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 241000196324 Embryophyta Species 0.000 claims abstract description 14
- 239000000341 volatile oil Substances 0.000 claims abstract description 14
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 13
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- 244000269722 Thea sinensis Species 0.000 claims abstract description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 11
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000003467 diminishing effect Effects 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- 238000001035 drying Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 241000222336 Ganoderma Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 238000004090 dissolution Methods 0.000 claims description 11
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 8
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 8
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 8
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 8
- 230000001194 anti-hemostatic effect Effects 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- 241001517299 Bulbophyllum Species 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 3
- 241000218176 Corydalis Species 0.000 claims description 3
- 244000124209 Crocus sativus Species 0.000 claims description 3
- 235000015655 Crocus sativus Nutrition 0.000 claims description 3
- 241000935235 Fritillaria meleagris Species 0.000 claims description 3
- 241000195947 Lycopodium Species 0.000 claims description 3
- 244000242564 Osmanthus fragrans Species 0.000 claims description 3
- 235000019083 Osmanthus fragrans Nutrition 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 3
- 239000004248 saffron Substances 0.000 claims description 3
- 235000013974 saffron Nutrition 0.000 claims description 3
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 abstract description 28
- 206010018276 Gingival bleeding Diseases 0.000 abstract description 8
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000002439 hemostatic effect Effects 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000011049 filling Methods 0.000 description 4
- 208000011759 gum bleeding Diseases 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000010641 Tooth disease Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003610 anti-gingivitis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to an oral care composition, and particularly discloses an efficacy agent of toothpaste with anti-inflammation and hemostatic effects, toothpaste containing the efficacy agent and a preparation method of the toothpaste. The efficacy agent comprises borneol and extract of lycopodium clavatum, or further comprises ganoderma lucidum extract, dendrobium officinale extract, gynostemma pentaphylla extract and tea polyphenol. According to the invention, the efficacy agent is added into the toothpaste, so that the toothpaste has the effects of diminishing inflammation and stopping bleeding, and after the plant essential oil and the auxiliary efficacy agent are further added, the bleeding index of the teeth of a subject can be better reduced, and the toothpaste has a good gingival bleeding resisting effect and has no adverse side effect.
Description
Technical Field
The invention relates to an oral care composition, in particular to an efficacy agent of toothpaste with anti-inflammation and hemostatic effects and toothpaste containing the same.
Background
With the development of society, the quality of life of people is continuously improved, the daily diet is also improved, various tooth diseases follow the daily diet, and gum bleeding is one of the most common tooth diseases.
The causes of gum bleeding are many, and gum bleeding caused by oral local factors is the most common. In order to solve these problems, attention must be paid to tooth cleaning to reduce the generation of plaque and tartar. Secondly, the gum nutrition is supplemented, the gum is repaired, and the gum immunity is improved, so that the problems of gum bleeding, inflammation and the like can be fundamentally solved.
The toothpaste is one of necessary articles for cleaning teeth, and the effect of only cleaning and whitening the teeth cannot meet the requirements of people, and the toothpaste is expected to have a certain treatment effect on oral problems. Aiming at the situations, the toothpaste with the efficacy is designed, and the toothpaste with the efficacy can clean and whiten teeth and has the efficacy of stopping bleeding and diminishing inflammation by adding a plurality of Chinese herbal medicine extracts.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide an efficacy agent of toothpaste with the effects of diminishing inflammation and stopping bleeding and toothpaste containing the efficacy agent.
In order to realize the purpose of the invention, the technical scheme of the invention is as follows:
in a first aspect, the invention provides an efficacy agent of an anti-inflammatory and hemostatic toothpaste, which comprises borneol and a lycopodium clavatum extract.
Further preferably, the efficacy agent comprises ganoderma lucidum extract, dendrobium officinale extract, gynostemma pentaphylla extract and tea polyphenol.
Further, the efficacy agent comprises 1-10 parts of borneol, 20-40 parts of lycopodium clavatum extract, 10-30 parts of lucid ganoderma extract, 20-40 parts of dendrobium officinale extract, 70-90 parts of gynostemma pentaphylla extract and 10-30 parts of tea polyphenol in parts by weight.
Further, the preparation method of the efficacy agent comprises the following steps:
(1) pulping the lycopodium clavatum, extracting with water for 1-3 times, adding 2-7 times of water each time, extracting for 0.5-1.5 hours, filtering, and drying the filtrate to obtain a lycopodium clavatum extract;
(2) crushing lucid ganoderma, sieving the smashed lucid ganoderma with a sieve of 10-16 meshes, decocting the lucid ganoderma with water for 2 hours, filtering out liquid medicine, finishing the first decoction, taking medicine residues, repeatedly decocting the medicine residues for one time, wherein the decocting time is 2 hours, finishing the second decoction, and the mass ratio of the lucid ganoderma to the water for the first decoction to the water for the second decoction is 1: (8-12): (8-12), combining the liquid medicines obtained by the two times of decoction, and drying to obtain the ganoderma lucidum extract;
(3) crushing the dendrobium officinale, sieving with a 10-16-mesh sieve, decocting with water for 1 hour, filtering out liquid medicine, completing first decoction, taking medicine residues, repeatedly decocting for two times, wherein the decocting time is 1 hour each time, completing second and third decoctions, and combining liquid medicine obtained by the three decoctions, wherein the mass ratio of the dendrobium officinale to the water for the first, second and third decoctions is 1: (15-25): (10-20): (10-20), drying to obtain the dendrobium officinale extract;
(4) mixing the crushed gynostemma pentaphylla with 10-20 times of water, extracting for 0.25-1 hour, decocting for 1-3 times, combining all extracting solutions, and drying to obtain a gynostemma pentaphylla extract;
(5) dissolving borneol, mixing with the lycopodium radiatum extract, the ganoderma lucidum extract, the dendrobium officinale extract, the gynostemma pentaphylla extract and the tea polyphenol, adding 3-5 times of water by weight, and mixing to obtain the efficacy agent.
In a second aspect, the invention provides a toothpaste with anti-inflammatory and hemostatic effects, which contains the aforementioned efficacy agent.
Further preferably, the toothpaste further comprises/is added with an auxiliary efficacy agent, the auxiliary efficacy agent is an extract of a traditional Chinese medicine composition, and the traditional Chinese medicine composition comprises the following raw materials in parts by weight or consists of the following raw materials in parts by weight: 1-7 parts of pseudo-ginseng, 1-10 parts of Hangzhou white chrysanthemum, 1-5 parts of rhizoma corydalis, 5-15 parts of radix scrophulariae, 1-7 parts of radix curcumae, 1-10 parts of radix paeoniae alba, 1-10 parts of thunberg fritillary bulb, 1-10 parts of radix tetrastigme, 0.1-1 part of saffron, 5-20 parts of dandelion and 1-5 parts of sweet osmanthus flower.
The preparation method of the auxiliary efficacy agent comprises the following steps: adding 5-20 times of water into the traditional Chinese medicine composition, decocting for 0.5-1.5 hours each time, extracting for 1-3 times, combining extracting solutions, and drying to obtain the traditional Chinese medicine composition.
Further preferably, the toothpaste further comprises/is added with plant essential oil, and the plant essential oil comprises or consists of the following components in parts by weight: 30-70 parts of grape seed oil, 30-70 parts of perilla seed oil and 30-70 parts of evening primrose oil.
It should be understood that the toothpaste containing the functional agent of the present invention, and the toothpaste further added with the aforementioned auxiliary functional agent and/or plant essential oil are within the scope of the present invention, and the preparation method thereof can be performed by the conventional method in the art, and can also be performed by the method disclosed in the embodiment of the present invention.
Taking toothpaste containing the above-mentioned efficacy agent, auxiliary efficacy agent and plant essential oil as an example, in the production of actual products, a toothpaste base is also needed to produce toothpaste products. In this case, as an illustrative example, the weight ratio of the used efficacy agent, auxiliary efficacy agent, plant essential oil and toothpaste base may be (5-20): (0.5-5): (0.5-5): (75-95).
The toothpaste matrix can be selected from toothpaste matrixes commonly used in the field, or can be composed of the following raw materials in parts by weight: 35-45 parts of a friction agent, 15-35 parts of an excipient, 1-7 parts of a foaming agent, 2-4 parts of a binder, 0.1-0.5 part of a sweetening agent, 0.2-1 part of a buffering agent and 0.1-0.7 part of a preservative.
In actual production, flavor additives such as essence can be added into the toothpaste matrix according to specific needs, for example, 0.1-1 part by weight of essence is added into the raw materials.
Further, in the toothpaste base:
the friction agent can be selected from one or more of hydrated silica, calcium hydrophosphate, aluminum hydroxide and calcium carbonate;
the excipient can be any one or combination of several of sorbitol, glycerol and polyethylene glycol;
the foaming agent can be sodium lauryl sulfate;
the binder can be any one or combination of several of carboxymethyl cellulose, carrageen crispus extract and xanthan gum;
the sweetener can be selected from saccharin sodium;
the buffer can be selected from sodium pyrophosphate buffers;
the preservative can be selected from sodium benzoate.
The invention further provides a specific preparation method of the toothpaste with the effects of diminishing inflammation and stopping bleeding as an illustrative example, and the preparation method specifically comprises the following steps:
preparing the following raw materials in parts by weight:
(1) preparing a B phase: heating deionized water to 50-60 ℃, adding sodium pyrophosphate, stirring for transparent dissolution, adding the other components of the phase B, and stirring uniformly for dissolution for later use;
(2) preparing a phase D: sequentially stirring and dissolving the D-phase components in deionized water for later use;
(3) mixing the glycerol and the polyethylene glycol-400 in the phase A, uniformly stirring, sequentially adding the other components in the phase A, and uniformly stirring;
then, adding a prepared phase B, adding a phase C after uniformly stirring, adding a prepared phase D after stirring until the phase C is dissolved, and uniformly stirring;
adding the phase E, stirring uniformly and discharging.
The raw materials or reagents involved in the invention are all common commercial products, and the operations involved are all routine operations in the field unless otherwise specified.
The above-described preferred conditions may be combined with each other to obtain a specific embodiment, in accordance with common knowledge in the art.
The invention has the beneficial effects that:
according to the invention, the toothpaste has the effects of diminishing inflammation and stopping bleeding by using the efficacy agent containing the borneol and the bulbophyllum radiatum extract, and the bleeding index of the teeth of a subject can be better reduced after the plant essential oil and the auxiliary efficacy agent are further added, so that the toothpaste has a good gingival bleeding resisting effect and has no adverse side effect.
Drawings
FIG. 1 shows the results of evaluation of Bleeding Index (BI) in example 5 of the present invention.
FIG. 2 shows the results of evaluation of the Gingival Index (GI) in example 5 of the present invention.
Detailed Description
Preferred embodiments of the present invention will be described in detail with reference to the following examples. It is to be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the present invention. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the spirit and scope of this invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
In a specific embodiment of the present invention, the preparation method of the used bulbophyllum radiatum extract comprises: pulping the lycopodium clavatum, extracting for 1-3 times, adding 2-7 times of water each time, extracting for 0.5-1.5 hours, filtering, and drying the filtrate to obtain the lycopodium clavatum extract.
In a specific embodiment of the present invention, the preparation method of the ganoderma lucidum extract comprises the following steps: crushing lucid ganoderma, sieving the smashed lucid ganoderma with a sieve of 10-16 meshes, decocting the lucid ganoderma with water for 2 hours, filtering out liquid medicine, finishing the first decoction, taking medicine residues, repeatedly decocting the medicine residues for one time, wherein the decocting time is 2 hours, finishing the second decoction, and the mass ratio of the lucid ganoderma to the water for the first decoction to the water for the second decoction is 1: (8-12): (8-12), combining the liquid medicines obtained by the two times of decoction, and drying to obtain the ganoderma lucidum extract.
In a specific embodiment of the invention, the preparation method of the dendrobium officinale extract comprises the following steps: crushing the dendrobium officinale, sieving with a 10-16-mesh sieve, decocting with water for 1 hour, filtering out liquid medicine, completing first decoction, taking medicine residues, repeatedly decocting for two times, wherein the decocting time is 1 hour each time, completing second and third decoctions, and combining liquid medicine obtained by the three decoctions, wherein the mass ratio of the dendrobium officinale to the water for the first, second and third decoctions is 1: (15-25): (10-20): (10-20), and drying to obtain the dendrobium officinale extract.
In a specific embodiment of the present invention, the preparation method of the gynostemma pentaphyllum extract used is: mixing the crushed gynostemma pentaphylla with 10-20 times of water, extracting for 0.25-1 hour, decocting for 1-3 times, combining all extracting solutions, and drying to obtain the gynostemma pentaphylla extract.
In the embodiment of the present invention, the borneol and the tea polyphenol are purchased from the market.
Example 1
This example illustrates a toothpaste containing the efficacy agent of the present invention having anti-inflammatory and hemostatic effects.
The preparation method of the toothpaste comprises the following steps:
(1) preparing the following raw materials in parts by weight:
a friction agent: 40 parts of calcium hydrophosphate;
excipient: 30 parts of a 70% sorbitol aqueous solution and 5 parts of glycerol;
foaming agent: 4 parts of sodium lauryl sulfate;
adhesive: 2 parts of sodium carboxymethyl cellulose;
an efficacy agent: 2 parts of bulbophyllum radiatum extract and 1 part of borneol;
essence: 0.1 part of menthol;
a sweetening agent: 0.3 part of saccharin sodium;
buffering agent: 0.4 part of sodium pyrophosphate;
preservative: 0.3 part of sodium benzoate.
(2) Slowly stirring 70% sorbitol aqueous solution, pouring into an emulsifying pot, heating while stirring, pouring sodium carboxymethylcellulose into the emulsifying pot, starting vacuum, and stirring until the paste is uniformly mixed and has no bubbles;
dissolving saccharin sodium in 2.6 times volume of 55 deg.C water, adding into emulsifying pot, vacuumizing, and stirring for 15 min;
dissolving herba Bulbophylli Inconspicui extract in 12 parts of water, adding sodium pyrophosphate at a temperature below 70 deg.C, and dissolving to obtain solution of efficacy agent;
grinding Borneolum Syntheticum into powder, adding glycerol, heating to 60 deg.C, and dissolving completely;
mixing calcium hydrogen phosphate and sodium benzoate, stirring, adding half of the mixture into an emulsifying pot, stirring for 20 min, adding the other half of the mixture into the emulsifying pot, adding the efficacy agent solution, vacuumizing, and stirring to obtain a fine paste. Pouring the dissolved borneol-glycerol into an emulsifying pot, starting vacuum and continuously stirring the mixture evenly to obtain fine paste.
Adding Mentholum into emulsifying pan, starting vacuum, and stirring for 10 min.
Sodium lauryl sulfate is poured in, vacuum is started, and stirring is carried out until complete dissolution.
And filling to obtain the toothpaste with the effects of diminishing inflammation and stopping bleeding.
Example 2
This example illustrates a toothpaste with anti-inflammatory and hemostatic effects, which contains the efficacy agent of the present invention, and the main difference from example 1 is that the efficacy agent of this example further contains ganoderma lucidum extract, dendrobium officinale extract, gynostemma pentaphyllum extract and tea polyphenols.
The preparation method of the toothpaste comprises the following steps:
(1) preparing the following raw materials in parts by weight:
preparing a B phase: weighing deionized water, heating to 50-60 ℃, adding sodium pyrophosphate, stirring for transparent dissolution, sequentially adding the rest components, and stirring for uniform dissolution for later use;
preparing a phase D: sequentially stirring and dissolving the D-phase components in deionized water for later use;
mixing the glycerol and the polyethylene glycol-400 in the phase A, starting the mixture, stirring the mixture uniformly at a medium speed, and then sequentially adding the rest components and stirring the mixture uniformly; then adding a pre-prepared phase B, changing the colloid into alkene, stirring at a low speed for 2-5 minutes, adding a phase C, starting medium-speed stirring until the phase C is stirred and dissolved, adding a pre-prepared phase D, and stirring for 2-5 minutes;
adding the phase E, uniformly stirring and discharging;
and filling to obtain the toothpaste with the effects of diminishing inflammation and stopping bleeding.
Example 3
This example is intended to illustrate a toothpaste having anti-inflammatory and hemostatic effects, which contains the efficacy agent of the present invention, and is different from example 2 mainly in that the toothpaste further contains an auxiliary efficacy agent.
The preparation method of the auxiliary efficacy agent comprises the following steps:
respectively taking 3 parts of pseudo-ginseng, 5 parts of chrysanthemum morifolium, 3 parts of rhizoma corydalis, 9 parts of radix scrophulariae, 3 parts of radix curcumae, 6 parts of radix paeoniae alba, 5 parts of thunberg fritillary bulb, 3 parts of radix tetrastigme, 1 part of saffron, 10 parts of dandelion and 2.5 parts of sweet osmanthus flower. Mixing, adding 15 times and 10 times of water, and decocting for 2 times, each for 1 hr. Mixing extractive solutions, filtering, concentrating, and drying to obtain mixed extract.
The preparation method of the toothpaste comprises the following steps:
(1) preparing the following raw materials in parts by weight:
preparing a B phase: weighing deionized water, heating to 50-60 ℃, adding sodium pyrophosphate, stirring for transparent dissolution, sequentially adding the rest components, and stirring for uniform dissolution for later use;
preparing a phase D: sequentially stirring and dissolving the D-phase components in deionized water for later use;
mixing the glycerol and the polyethylene glycol-400 in the phase A, starting the mixture, stirring the mixture uniformly at a medium speed, and then sequentially adding the rest components and stirring the mixture uniformly; then adding a pre-prepared phase B, changing the colloid into alkene, stirring at a low speed for 2-5 minutes, adding a phase C, starting medium-speed stirring until the phase C is stirred and dissolved, adding a pre-prepared phase D, and stirring for 2-5 minutes;
adding the phase E, uniformly stirring and discharging;
and filling to obtain the toothpaste with the effects of diminishing inflammation and stopping bleeding.
Example 4
This example illustrates a toothpaste with anti-inflammatory and hemostatic effects, which contains the efficacy agent of the present invention, and is different from example 3 mainly in that the toothpaste further contains plant essential oils.
The preparation method of the toothpaste comprises the following steps:
(1) preparing the following raw materials in parts by weight:
preparing a B phase: weighing deionized water, heating to 50-60 ℃, adding sodium pyrophosphate, stirring for transparent dissolution, sequentially adding the rest components, and stirring for uniform dissolution for later use;
preparing a phase D: sequentially stirring and dissolving the D-phase components in deionized water for later use;
mixing the glycerol and the polyethylene glycol-400 in the phase A, starting the mixture, stirring the mixture uniformly at a medium speed, and then sequentially adding the rest components and stirring the mixture uniformly; then adding a pre-prepared phase B, changing the colloid into alkene, stirring at a low speed for 2-5 minutes, adding a phase C, starting medium-speed stirring until the phase C is stirred and dissolved, adding a pre-prepared phase D, and stirring for 2-5 minutes;
adding the phase E, uniformly stirring and discharging;
and filling to obtain the toothpaste with the effects of diminishing inflammation and stopping bleeding.
Example 5
The toothpaste prepared in examples 1, 2, 3 and 4 was used as a control for evaluating the efficacy of suppressing gingival bleeding and reducing gingival inflammation in experimental groups 1, 2, 3 and 4, respectively, in comparison with a commercially available brand of toothpaste.
The tested population is healthy female/male, 18-65 years old and 100 people in total, is randomly divided into 5 groups, and is tested before the test to obtain an initial average value, and after 12 weeks, the test is carried out to calculate the values of each group.
1. Bleeding Index (BI) assessment
Bleeding index scoring criteria:
0 min-healthy gum, no inflammation and bleeding
1 minute-inflammatory change of gum color, no bleeding of probe
2 min-some bleeding after probing
3 min-bleeding with the Probe and spreading along the gingival margin
4 fen-full bleeding and overflow of gingival sulcus
5 min-automatic bleeding
The checking method comprises the following steps: the gingival sulcus or pocket is gently probed with a blunt periodontal probe, and the presence and extent of bleeding is observed 30 seconds after the probe is removed.
2. Gingival Index (GI) assessment
Gingival index scoring standard:
0 min-normal gingiva
Score 1-mild inflammation: slight change of gum color, mild hyperemia, no bleeding by probing
Score 2-moderate inflammation: bleeding, edema, slippery and spying bleeding of gum
Score 3-severe inflammation: gingival congestion, edema, ulcer, spontaneous hemorrhage
The checking method comprises the following steps: a blunt periodontal probe was used, combining visual and exploratory examinations. The gingiva around each tooth of the whole mouth was examined, and the surrounding gingiva was divided into buccal-mesial, buccal-central, buccal-distal and palatal. The score for each tooth was the average of 4 facer scores, all tested per person.
3. Evaluation results
As shown in table 1 and fig. 1, after 12 weeks using the toothpastes prepared in examples 1 to 4 of the present invention, the tested tooth bleeding index of the subject showed a result significantly lower than the initial value and also significantly lower than that of the control group, indicating that the product of the present invention has an anti-gingival bleeding effect.
Moreover, as can be seen from table 1 and fig. 1, the toothpaste containing the ganoderma lucidum extract, the dendrobium officinale extract, the gynostemma pentaphyllum extract and the tea polyphenol as the efficacy agent (experimental group 2) and the toothpaste containing the auxiliary efficacy agent (experimental group 3) and the plant essential oil (experimental group 4) can better reduce the bleeding index of the teeth of the subject.
TABLE 1 bleeding index BI values
As shown in table 2 and fig. 2, after 12 weeks using the toothpastes prepared in examples 1-4 of the present invention, the tested gingival index of the subject showed significantly lower results than the initial value and also significantly lower results than the control group, indicating that the product of the present invention has anti-gingivitis effect.
Moreover, as can be seen from table 2 and fig. 2, the toothpaste containing the ganoderma lucidum extract, the dendrobium officinale extract, the gynostemma pentaphyllum extract and the tea polyphenol in the efficacy agent (experimental group 2) and the toothpaste containing the auxiliary efficacy agent (experimental group 3) and the plant essential oil (experimental group 4) can better reduce the gingival index of the subject.
TABLE 2 gingival index GI values
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. An efficacy agent of toothpaste with the effects of diminishing inflammation and stopping bleeding is characterized by comprising borneol and a lycopodium radiatum extract.
2. The agent of claim 1, wherein the agent comprises ganoderma lucidum extract, dendrobium officinale extract, gynostemma pentaphyllum extract, and tea polyphenols.
3. The efficacy agent according to claim 2, wherein the efficacy agent comprises 1 to 10 parts by weight of borneol, 20 to 40 parts by weight of bulbophyllum radiatum, 10 to 30 parts by weight of ganoderma lucidum extract, 20 to 40 parts by weight of dendrobium officinale extract, 70 to 90 parts by weight of gynostemma pentaphyllum extract and 10 to 30 parts by weight of tea polyphenol.
4. The efficacy agent according to claim 3, wherein the preparation method of the efficacy agent comprises the following steps:
(1) pulping the lycopodium clavatum, extracting with water for 1-3 times, adding 2-7 times of water each time, extracting for 0.5-1.5 hours, filtering, and drying the filtrate to obtain a lycopodium clavatum extract;
(2) crushing lucid ganoderma, sieving the smashed lucid ganoderma with a sieve of 10-16 meshes, decocting the lucid ganoderma with water for 2 hours, filtering out liquid medicine, finishing the first decoction, taking medicine residues, repeatedly decocting the medicine residues for one time, wherein the decocting time is 2 hours, finishing the second decoction, and the mass ratio of the lucid ganoderma to the water for the first decoction to the water for the second decoction is 1: (8-12): (8-12), combining the liquid medicines obtained by the two times of decoction, and drying to obtain the ganoderma lucidum extract;
(3) crushing the dendrobium officinale, sieving with a 10-16-mesh sieve, decocting with water for 1 hour, filtering out liquid medicine, completing first decoction, taking medicine residues, repeatedly decocting for two times, wherein the decocting time is 1 hour each time, completing second and third decoctions, and combining liquid medicine obtained by the three decoctions, wherein the mass ratio of the dendrobium officinale to the water for the first, second and third decoctions is 1: (15-25): (10-20): (10-20), drying to obtain the dendrobium officinale extract;
(4) mixing the crushed gynostemma pentaphylla with 10-20 times of water, extracting for 0.25-1 hour, decocting for 1-3 times, combining all extracting solutions, and drying to obtain a gynostemma pentaphylla extract;
(5) dissolving borneol, mixing with the lycopodium radiatum extract, the ganoderma lucidum extract, the dendrobium officinale extract, the gynostemma pentaphylla extract and the tea polyphenol, adding 3-5 times of water by weight, and mixing to obtain the efficacy agent.
5. A toothpaste having anti-inflammatory and hemostatic effects, which comprises the agent according to any one of claims 1 to 4.
6. The toothpaste according to claim 5, wherein the toothpaste contains an auxiliary efficacy agent, the auxiliary efficacy agent is an extract of a traditional Chinese medicine composition, and the traditional Chinese medicine composition comprises or consists of the following raw materials in parts by weight: 1-7 parts of pseudo-ginseng, 1-10 parts of Hangzhou white chrysanthemum, 1-5 parts of rhizoma corydalis, 5-15 parts of radix scrophulariae, 1-7 parts of radix curcumae, 1-10 parts of radix paeoniae alba, 1-10 parts of thunberg fritillary bulb, 1-10 parts of radix tetrastigme, 0.1-1 part of saffron, 5-20 parts of dandelion and 1-5 parts of sweet osmanthus flower.
7. The toothpaste according to claim 6, wherein the auxiliary efficacy agent is prepared by: adding 5-20 times of water into the traditional Chinese medicine composition, decocting for 0.5-1.5 hours each time, extracting for 1-3 times, combining extracting solutions, and drying to obtain the traditional Chinese medicine composition.
8. The toothpaste according to any one of claims 5 to 7, wherein the toothpaste comprises plant essential oil, and the plant essential oil comprises or consists of the following components in parts by weight: 30-70 parts of grape seed oil, 30-70 parts of perilla seed oil and 30-70 parts of evening primrose oil.
9. The toothpaste according to claim 8, wherein the toothpaste comprises an efficacy agent, an auxiliary efficacy agent, a plant essential oil and a toothpaste base, and the weight ratio of the efficacy agent, the auxiliary efficacy agent, the plant essential oil and the toothpaste base is (5-20): (0.5-5): (0.5-5): (75-95).
10. The toothpaste according to claim 9, wherein the toothpaste is prepared by a method comprising:
preparing the following raw materials in parts by weight:
(1) preparing a B phase: heating deionized water to 50-60 ℃, adding sodium pyrophosphate, stirring for transparent dissolution, adding the other components of the phase B, and stirring uniformly for dissolution for later use;
(2) preparing a phase D: sequentially stirring and dissolving the D-phase components in deionized water for later use;
(3) mixing the glycerol and the polyethylene glycol-400 in the phase A, uniformly stirring, sequentially adding the other components in the phase A, and uniformly stirring;
then, adding a prepared phase B, adding a phase C after uniformly stirring, adding a prepared phase D after stirring until the phase C is dissolved, and uniformly stirring;
adding the phase E, stirring uniformly and discharging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010002447.8A CN110917059A (en) | 2020-01-02 | 2020-01-02 | Efficacy agent of toothpaste with anti-inflammation and hemostasis effects, toothpaste containing efficacy agent and preparation method of toothpaste |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010002447.8A CN110917059A (en) | 2020-01-02 | 2020-01-02 | Efficacy agent of toothpaste with anti-inflammation and hemostasis effects, toothpaste containing efficacy agent and preparation method of toothpaste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110917059A true CN110917059A (en) | 2020-03-27 |
Family
ID=69854308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010002447.8A Pending CN110917059A (en) | 2020-01-02 | 2020-01-02 | Efficacy agent of toothpaste with anti-inflammation and hemostasis effects, toothpaste containing efficacy agent and preparation method of toothpaste |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110917059A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111481487A (en) * | 2020-04-22 | 2020-08-04 | 名臣健康用品股份有限公司 | Whitening skin care composition containing bulbophyllum radiatum extract and preparation method thereof |
| CN111956549A (en) * | 2020-08-27 | 2020-11-20 | 上海蔚艺生物科技有限公司 | Toothpaste with compatibility of plant essences and application of toothpaste |
| CN112137938A (en) * | 2020-11-03 | 2020-12-29 | 广州市盛龙口腔清洁用品有限公司 | Gynostemma pentaphylla traditional Chinese medicine toothpaste |
| CN112156046A (en) * | 2020-10-22 | 2021-01-01 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method, product and application of kyanite antibacterial and anti-inflammatory multifunctional toothpaste |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547490A (en) * | 2015-01-04 | 2015-04-29 | 海南蛛王药业有限公司 | Medicine for treating periodontal disease and preparation method of medicine |
| CN105997774A (en) * | 2016-05-10 | 2016-10-12 | 芜湖亮晶晶生物科技有限公司 | Hemostatic and anti-inflammatory toothpaste and preparation method thereof |
| CN108309878A (en) * | 2018-05-17 | 2018-07-24 | 广东康王日化有限公司 | A kind of natural borneol toothpaste and preparation method thereof |
-
2020
- 2020-01-02 CN CN202010002447.8A patent/CN110917059A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547490A (en) * | 2015-01-04 | 2015-04-29 | 海南蛛王药业有限公司 | Medicine for treating periodontal disease and preparation method of medicine |
| CN105997774A (en) * | 2016-05-10 | 2016-10-12 | 芜湖亮晶晶生物科技有限公司 | Hemostatic and anti-inflammatory toothpaste and preparation method thereof |
| CN108309878A (en) * | 2018-05-17 | 2018-07-24 | 广东康王日化有限公司 | A kind of natural borneol toothpaste and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈功锡: "《湘西药用植物资源开发与可持续利用》", 31 May 2015, 西南交通大学出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111481487A (en) * | 2020-04-22 | 2020-08-04 | 名臣健康用品股份有限公司 | Whitening skin care composition containing bulbophyllum radiatum extract and preparation method thereof |
| CN111481487B (en) * | 2020-04-22 | 2023-11-03 | 名臣健康用品股份有限公司 | Whitening skin care composition containing herba Violae extract and preparation method thereof |
| CN111956549A (en) * | 2020-08-27 | 2020-11-20 | 上海蔚艺生物科技有限公司 | Toothpaste with compatibility of plant essences and application of toothpaste |
| CN112156046A (en) * | 2020-10-22 | 2021-01-01 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method, product and application of kyanite antibacterial and anti-inflammatory multifunctional toothpaste |
| CN112137938A (en) * | 2020-11-03 | 2020-12-29 | 广州市盛龙口腔清洁用品有限公司 | Gynostemma pentaphylla traditional Chinese medicine toothpaste |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110917059A (en) | Efficacy agent of toothpaste with anti-inflammation and hemostasis effects, toothpaste containing efficacy agent and preparation method of toothpaste | |
| CN103520052B (en) | Bletilla striata extract is preparing the application in oral care product | |
| CN104207982A (en) | Traditional Chinese medicine composition for preventing oral inflammation and oral care product containing same | |
| CN103520076B (en) | Compound Chinese medicine extract is preparing the application in oral cavity nursing health products | |
| CN105055223A (en) | Traditional Chinese medicine toothpaste capable of stopping bleeding and desensitizing | |
| CN104840388A (en) | Application of plant extracts to oral care products | |
| CN107982084B (en) | A kind of toothpaste of the rare saponin(e containing Radix Notoginseng and preparation method thereof | |
| CN106535911B (en) | Oral composition for periodontitis prevention and treatment containing Morus alba extract and Euonymus extract as active ingredients | |
| CN104840391B (en) | Application of the blade of grass horse hair algae extract in anti-caries oral care implement | |
| CN102986964A (en) | Eucommiae tea beverage and preparation method thereof | |
| CN103505387A (en) | Dendrobium huoshanense facial cleanser and preparation method thereof | |
| CN106377481B (en) | A method for extracting rhizoma Cyperi extract, and toothpaste and collutory containing the same | |
| CN103536483B (en) | Radix Sangusorbae extract is preparing the application in oral care product | |
| CN105919892A (en) | Hazelnut flavor mouth wash and preparation method thereof | |
| CN106138196B (en) | Toothpaste containing pseudo-ginseng extract and lamiophlomis rotata extract and preparation method thereof | |
| CN103301046A (en) | Chinese herbal medicine toothpaste containing pseudo-ginseng saponin and pine needle extract | |
| CN103520054B (en) | Ramulus Uncariae Cum Uncis extract application in preparing oral care product | |
| CN112691056A (en) | Preparation process of medicinal toothpaste for reducing internal heat | |
| CN103655301A (en) | Tooth paste containing artemisia rupestris extract and preparation method thereof | |
| CN106511821A (en) | Pharmaceutical composition with effects of clearing heat, nourishing yin, promoting secretion of saliva or body fluid and stopping bleeding and preparation method of pharmaceutical composition | |
| CN106551850A (en) | A kind of promoting and tooth-building toothpaste | |
| CN105853316A (en) | Toothpaste and preparation method thereof | |
| CN113694003A (en) | Sea salt bactericidal and bacteriostatic mouth wash and preparation method thereof | |
| CN103536482A (en) | Application of caulis sinomenii extract and radix sanguisorbae extract in preparing oral care product | |
| US11771644B1 (en) | Whitening toothpaste capable of effectively removing dental plaque and tartar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |